Medpace (NASDAQ:MEDP) Shares Unloaded Rep. David Taylor

Key Points

• Representative David Taylor sold shares of Medpace Holdings, Inc. worth between $1,001 and $15,000 on July 23rd, as disclosed in a filing.
• Medpace reported earnings of $3.10 per share for the last quarter, exceeding analyst expectations by $0.10, and forecasted FY 2025 EPS guidance between 13.760 and 14.53.
• Recent analyst ratings have been mixed, with some downgrading Medpace to a "sell" and others maintaining a "hold" rating, leading to a consensus target price of $412.73.

Representative David Taylor (R-Ohio) recently sold shares of Medpace Holdings, Inc. (NASDAQ:MEDP). In a filing disclosed on September 02nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Medpace stock on July 23rd. The trade occurred in the Representative's "DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) - DAVE" account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 8/14/2025.
• Purchased $1,001 - $15,000 in shares of Marathon Petroleum NYSE: MPC on 8/14/2025.
• Purchased $15,001 - $50,000 in shares of Eli Lilly and Company NYSE: LLY on 8/14/2025.
• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 8/14/2025.
• Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 8/13/2025.
• Sold $1,001 - $15,000 in shares of Installed Building Products NYSE: IBP on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Salesforce NYSE: CRM on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 8/7/2025.

Medpace Price Performance

Shares of MEDP stock opened at $481.23 on Thursday. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $501.30. The stock's 50-day moving average is $405.65 and its 200 day moving average is $342.20. The company has a market cap of $13.52 billion, a P/E ratio of 35.78, a PEG ratio of 2.99 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same quarter last year, the company earned $2.75 earnings per share. The firm's revenue for the quarter was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of recent research reports. Cowen downgraded Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. William Blair reaffirmed a "market perform" rating on shares of Medpace in a research report on Wednesday, July 23rd. Truist Financial raised their price objective on Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. UBS Group downgraded Medpace from a "neutral" rating to a "sell" rating and raised their price target for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. Finally, Rothschild & Co Redburn downgraded Medpace from a "buy" rating to a "neutral" rating and raised their price target for the stock from $342.00 to $474.00 in a report on Wednesday. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Reduce" and a consensus target price of $412.73.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of MEDP. Geneos Wealth Management Inc. raised its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after acquiring an additional 37 shares in the last quarter. Brooklyn Investment Group raised its position in Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after acquiring an additional 71 shares in the last quarter. Whittier Trust Co. raised its position in Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after acquiring an additional 35 shares in the last quarter. Employees Retirement System of Texas purchased a new position in Medpace during the second quarter valued at approximately $36,000. Finally, Colonial Trust Co SC increased its position in shares of Medpace by 150.0% in the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock valued at $58,000 after buying an additional 105 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, VP Susan E. Burwig sold 7,500 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.14, for a total value of $3,376,050.00. Following the completion of the sale, the vice president directly owned 57,500 shares in the company, valued at $25,883,050. The trade was a 11.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Kevin M. Brady sold 12,000 shares of the business's stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total value of $5,450,760.00. Following the completion of the sale, the chief financial officer owned 6,000 shares of the company's stock, valued at $2,725,380. This trade represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 151,266 shares of company stock valued at $69,311,427. 20.30% of the stock is owned by insiders.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio's 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Taylor (Republican Party) ran for election to the U.S. House to represent Ohio's 2nd Congressional District. He won in the general election on November 5, 2024. David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor's career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.